Kazu Okuma

Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants

Saya Moriyama, Yu Adachi, Takashi Sato et al. · Immunity · 2021 · 154 citations · Full text

Life Sciences, Immunology, Infectious Diseases +15

Incidence of human T-lymphotropic virus 1 infection in adolescent and adult blood donors in Japan: a nationwide retrospective cohort analysis

Masahiro Satake, Masako Iwanaga, Yasuko Sagara et al. · The Lancet Infectious Diseases · 2016 · 126 citations

Public Health, Immunology, Infectious Diseases +8

Host Range of Human T-Cell Leukemia Virus Type I Analyzed by a Cell Fusion-Dependent Reporter Gene Activation Assay

Kazu Okuma, Minoru Nakamura, Shuji Nakano et al. · Virology · 1999 · 118 citations

Life Sciences, Genetics, Molecular Biology +11

Virus Entry Is a Major Determinant of Cell Tropism of Edmonston and Wild-Type Strains of Measles Virus as Revealed by Vesicular Stomatitis Virus Pseudotypes Bearing Their Envelope Proteins

Hironobu Tatsuo, Kazu Okuma, Kotaro Tanaka et al. · Journal of Virology · 2000 · 98 citations

Life Sciences, Infectious Diseases, Molecular Biology +16

The Novel CXCR4 Antagonist KRH-3955 Is an Orally Bioavailable and Extremely Potent Inhibitor of Human Immunodeficiency Virus Type 1 Infection: Comparative Studies with AMD3100

Tsutomu Murakami, Sei Kumakura, Tōru Yamazaki et al. · Antimicrobial Agents and Chemotherapy · 2009 · 58 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16